KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Acadia Pharmaceuticals (ACAD) EBT Margin (2016 - 2025)

Acadia Pharmaceuticals (ACAD) has 15 years of EBT Margin data on record, last reported at 9.06% in Q4 2025.

  • For Q4 2025, EBT Margin rose 1525.0% year-over-year to 9.06%; the TTM value through Dec 2025 reached 12.85%, up 447.0%, while the annual FY2025 figure was 12.96%, 1398.0% down from the prior year.
  • EBT Margin reached 9.06% in Q4 2025 per ACAD's latest filing, down from 16.01% in the prior quarter.
  • Across five years, EBT Margin topped out at 17.18% in Q4 2023 and bottomed at 97.52% in Q1 2022.
  • Average EBT Margin over 5 years is 13.61%, with a median of 8.72% recorded in 2024.
  • Peak YoY movement for EBT Margin: crashed -3518bps in 2022, then surged 5958bps in 2023.
  • A 5-year view of EBT Margin shows it stood at 32.81% in 2021, then grew by 9bps to 29.92% in 2022, then surged by 157bps to 17.18% in 2023, then tumbled by -136bps to 6.2% in 2024, then surged by 246bps to 9.06% in 2025.
  • Per Business Quant database, its latest 3 readings for EBT Margin were 9.06% in Q4 2025, 16.01% in Q3 2025, and 15.19% in Q2 2025.